A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Category: Xarelto – Rivaroxaban

  • Top 10 Publications on Thrombosis and Anticoagulation from 2012

    Stephan Moll writes… 2012 has been a year with significant progress in the field of venous thromboembolism and anticoagulation.  The three most noteworthy, clinically relevant developments were probably (a) the publication of the new ACCP (American College of Chest Physician) guidelines on antithrombotic therapy in February 2012; (b)  The FDA-approval of rivaroxaban (Xarelto) in November 2012 for the acute…

  • Xarelto (Rivaroxaban) – Hospital Guideline

    Stephan Moll, MD writes… Xarelto® is FDA approved for treatment of venous thromboembolism (VTE), prevention of VTE after hip and knee replacement  surgery, and for atrial fibrillation.   A number of practical management questions are encountered by physicians, pharmacists, and other health care professional taking care of patients on Xarelto®, such as (a) dosing in…

  • Xarelto (Rivaroxaban): FDA Approved for DVT and PE Treatment

    Stephan Moll, MD writes… Today is a very exciting day for patients and health care professionals: the oral anticoagulant Xarelto® (rivaroxaban) was FDA approved today (Nov 2nd, 2012) for the use in patients with DVT and PE – for the acute treatment of DVT and PE, as well as for the secondary long-term prevention of…

  • Rivaroxaban (Xarelto) and PE

    Stephan Moll, MD writes… Good news: The large phase 3 clinical trial comparing 3-12 months treatment of Rivaroxaban (Xarelto) with warfarin in patients with newly diagnosed pulmonary embolism was published on 3-26-2012 in the New England Journal of Medicine [reference 1], showing that Rivaroxaban was (a) noninferior to warfarin in its efficacy, (b) caused the…

  • Xarelto and DVT – Approved in Europe

    Xarelto (Rivaroxaban) was approved in Europe today (Dec 19th, 2011) for patients with acute DVT. This is good news

  • Another New Blood Thinner FDA Approved : Xarelto (Rivaroxaban)

    Today the FDA approved Xarelto (Rivaroxaban) for irregular heart beat (= atrial fibrillation = a. fib).  The approved dose is 20 mg once daily.  The link to the FDA press release is here.  The Xarelto prescribing information can be found here. Xarelto for Blood Clots in the Veins (DVT and PE)

  • Xarelto (Rivaroxaban) Approved For A. Fib

    Today the FDA approved Xarelto (Rivaroxaban) for atrial fibrillation.  The approved dose is 20 mg once daily. The link to the FDA press release is here.  The Xarelto prescribing information can be found here. Xarelto for Venous Thromboembolism Xarelto is NOT approved at this point for treatment of DVT or PE

  • Rivaroxaban (Xarelto): Advisory Board to the FDA Recommends Approval for Atrial Fibrillation

    The external advisory board to the FDA recommended today (Sept 8th, 2011) to approve Rivaroxaban (Xarelto) for the stroke prevention in atrial fibrillation.  More details about the vote can be found here.  Today’s recommendation is contrary to the one given by an internal FDA review committee which had recommended 2 days ago to NOT approve the…